Exin Therapeutics, Inc.
New Form D on file · 2026-02-10 · the record
What the record says
Trailing twelve months. 716 filings in Biotechnology, totalled by week. The dot is this raise, $2.16M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Company officers on record
Gabriel Ocana Santero is named as Executive Officer and Director on the Form D that Exin Therapeutics, Inc. filed with the SEC on 10 February 2026, one of 3 people that filing names.
Ivan Alex Priela Lazarte is named as Executive Officer and Director on the Form D that Exin Therapeutics, Inc. filed with the SEC on 10 February 2026, one of 3 people that filing names.
Marko Tvrdic is named as Executive Officer and Director on the Form D that Exin Therapeutics, Inc. filed with the SEC on 10 February 2026, one of 3 people that filing names.
3 people named on the filing — 3 holding an executive role.
Named as of the 2026-02-10 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
- 3 people named on the filing — 3 holding an executive role.
No investor is drawn from a Form D — the form states how many invested and never who.
The full profile
Source Check, INVEST, RECRUIT and Press Requests on Exin Therapeutics, Inc.
- Source Check — verify Gabriel Ocana Santero's other claims against the registers that hold them.
- INVEST — size up this raise on the figures the filing states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with Gabriel Ocana Santero for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Exin Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Exin Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. FoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.